Sanofi Pasteur's paediatric pentavalent vaccine Shan5 passes WHO prequalification status.
M2 EQUITYBITES-May 5, 2014-Sanofi Pasteur's paediatric pentavalent vaccine Shan5 passes WHO prequalification status
(C)2014 M2 COMMUNICATIONS http://www.m2.com
Sanofi Pasteur, the vaccines division of Sanofi (NYSE:SNY), stated on Monday that its paediatric pentavalent vaccine Shan5 has been awarded prequalification status from the World Health Organisation (WHO).
The company said that Shan5 was developed by its affiliate Shantha Biotechnics in Hyderabad, India.
Produced at Shantha's state-of-the-art manufacturing facility in Hyderabad, Shan5 received Marketing Authorisation in India in March 2014. According to Sanofi Pasteur it is a fully-liquid five-in-one, convenient, safe and high-quality vaccine that provides effective protection for children from six weeks of age against diphtheria, tetanus, pertussis, Hib & hepatitis B.
This prequalification status is based on a review of a comprehensive set of data related to the process and the product characteristics, as well as on a positive recommendation of WHO auditors following a site inspection of Shantha's manufacturing facilities. Shan5 vaccine is now qualified for purchase by United Nations agencies, mainly UNICEF.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||May 5, 2014|
|Previous Article:||Lpath announces Fast-Track SBIR grant for IND-enabling studies of Lpathomab for Traumatic Brain Injury.|
|Next Article:||Argus, IHS expand API coal index in Asia-Pacific.|